Baroreflex Activation Therapy for Heart Failure

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1090 participants.

Also called NCT02627196

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,090 participants (enrolled count) (from the registry)
Sponsor
CVRx, Inc. (from the registry)
Registry
  • NCT NCT02627196
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02627196. Randomized; no masking; primary purpose treatment. Start 2016-04-19 (actual); primary completion 2023-10 (actual). Results posted on 2026-03-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Baroreflex Activation Therapy for Heart Failure
Acronym
BeAT-HF
Condition
Heart Failure
Intervention (Device)
BAROSTIM NEO® System
Intervention (Drug)
Medical Management
Lead sponsor
CVRx, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02627196
Content hash
aa688c9202c718711242c2604ec6813e6a0276e64f2a1cecbddb39d873b6fe8c